It was established that the administration of an aqueous solution of bis(µ-tartrato)di(μ-hydroxy) germanate (IV) triethanolammonium to animals daily for 2 months at a dose of the active substance of 10 mg/kg of the animal's weight leads to inhibition of the total activity of the alkaline phospholipase A2 of mononuclear cells. The results of the study can be used to correct lipid metabolism in the development of disorders in hyperlipidemia. This makes it possible to expand the scope of use of the studied substance and create new pharmaceuticals based on bis(µ-tartrato)di(μ-hydroxy) germanate (IV) triethanolammonium prevent and inhibit the development of hyperlipidemia.
Keywords: alkaline phospholipase A2; atherosclerosis; bis(μ-tartrato)di(μ-hydroxy) germanate (IV) triethanolammonium; hyperlipidemia.